AtheroNova Inc. Announces Russian Ministry Of Healthcare Approval For Initiation Of Phase 1b Trial Investigating AHRO-001

IRVINE, Calif., May 28, 2014 (GLOBE NEWSWIRE) -- AtheroNova Inc. (OTCBB:AHRO), a biotech company focused on the research and development of compounds to safely regress atherosclerotic plaque and improve lipid profiles in humans, today announced that its partner, CardioNova, received approval from the Russian Ministry of Healthcare to begin a Phase 1b clinical trial extension for AHRO-001. This Phase 1b trial will be a continuation of the successful AHRO-001 Phase 1 safety trial completed in February 2014, in which patients were dosed with AHRO-001 for up to three weeks.

Help employers find you! Check out all the jobs and post your resume.